![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Combined lenalidomide, low‐dose dexamethasone, and rituximab achieves durable responses in rituximab‐resistant indolent and mantle cell lymphomas
Publisher: John Wiley & Sons Inc
E-ISSN: 1097-0142|120|2|222-228
ISSN: 0008-543x
Source: CANCER, Vol.120, Iss.2, 2014-01, pp. : 222-228
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)